METHODS: Forty H22 tumor-bearing mice were randomly divided into 4 groups (n = 10), model control group and cyclophosphamide (CTX) group. Chenodeoxycholic acid-Ver intraperitoneal injection group and CDCA-Ver intravenous injection group. The model control group was injected intraperitoneally with 10 ml L · kg-1 aseptic 0.9% sodium chloride solution once a day. The CTX group was injected intraperitoneally once a day at 20 mg · kg-1 dose. Daily injection of 20 mg · kg-1 dose once a day, CDCA-Ver intravenous injection group daily by 20 mg · kg-1 dose of mouse tail vein injection 1 times. After administration for 24 h, the dose was 0.1 m L · (10 g) -1 and 10 d continuous administration. To investigate the inhibitory effect of CDCA-Ver on the growth of tumor-bearing mice, and to evaluate the effect of CDCA-Ver on the immune organ index (thymus index and spleen index) of tumor-bearing mice. The effect of CDCA-Ver on the histopathology of tumor-bearing mice was studied by histopathological section method. RESULTS: Both chenodeoxycholic acid -Ver intravenous and intraperitoneal injection had a good inhibitory effect on the tumor growth of tumor-bearing mice. The intraperitoneal injection of 20 mg · kg-1 dose of CDCA-Ver was 48.3% The difference between the model control group was statistically significant (P <0.05), and the effect was similar to that of the CTX group. Compared with the model control group, the spleen index and thymus index of CDCA-Ver intraperitoneal injection group did not change significantly (P <0.05), while the spleen index and thymus index of CTX group were significantly decreased (P <0.01), indicating that CDCA-Ver Antitumor effect does not reduce the immune function of tumor-bearing mice. Histopathological results also confirmed that CDCA-Ver has antitumor effects in vivo. Conclusion: chenodeoxycholic acid-Ver can inhibit the tumor growth of H22 tumor bearing mice.